中文名称 |
Honokiol
|
||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
中文别名 |
厚朴酚;和厚朴酚;3',5-二-2-丙烯基-1,1'-联苯-2,4'-二酚;Honokiol 和厚朴酚;WAKO083-08511和厚朴酚;和厚朴酚 EP标准品;和厚朴酚 Honokiol;和厚朴酚 标准品;和厚朴酚(P);和厚朴酚(标准品);和厚朴酚, 来源于厚朴;和厚朴酚,Honokiol,植物提取物,标准品,对照品;厚朴酚\和厚朴酚;厚朴酚厚朴总酚;厚朴提取物;厚朴油;3',5'-二-2-丙烯基-1,1'-联苯-2,4'-二酚;3',5'-二烯丙基-2,4'-二羟基联苯;3',5-二烯丙基联苯-2,4'-二醇
|
||||||||||||
英文名称 |
Honokiol
|
||||||||||||
英文别名 |
5,3'-Diallyl-2,4'-dihydroxybiphenyl;Honokiol;3,3'-DIALLYL-4,6'-DIHYDROXYBIPHENYL;HONOKIOL(P) PrintBack;HONOKIOL(RG);NSC 293100;3',5-Diallyl-2,4'-biphenyldiol;3',5-Diallyl-2,4'-dihydroxybiphenyl;3',5-Diallylbiphenyl-2,4'-diol;5,3'-DIALLYL-2,4'-DIHYDROXYDIPHENYL;5,3'-diallyl-biphenyl-2,4'-diol;5,5'-diallyl-2,4'-dihydroxybiphenyl;HONEYSUCKLEFLOWEREXTRACT;NSC-293100;Magnolia bark oil;5,3′-Diallyl-2,4′-dihydroxybiphenyl;Magnolol oil;3,5'-Diallyl-4,2'-dihydroxybiphenyl;Honokiol,(S);C18H18O2;CPD000387107;3',5-diallyl-[1,1'-biphenyl]-2,4'-diol;4-allyl-2-(3-allyl-4-hydroxy-phenyl)phenol;11513CCO0N;[1,1'-Biphenyl]-2,4'-diol, 3',5-di-2-propenyl-;SMR000387107;3',5-di(prop-2-en-1-yl)biphenyl-2,4'-diol;Honokiol, HO;5,3′5,3′-Dially
|
||||||||||||
Cas No. |
35354-74-6
|
||||||||||||
分子式 |
C18H18O2
|
||||||||||||
分子量 |
266.33
|
||||||||||||
包装储存 |
|
生物活性 |
Honokiol is a bioactive, biphenolic phytochemical that possesses potent antioxidative, anti-inflammatory, antiangiogenic, and anticancer activities by targeting a variety of signaling molecules. It inhibits the activation of Akt. Honokiol can readily cross the blood brain barrier. |
||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
性状 |
Solid |
||||||||||||
IC50 & Target[1][2] |
|
||||||||||||
体外研究(In Vitro) |
Honokiol (0, 12.5, 25 and 50 μM) inhibits the growth of GBM cells and induces apoptosis, with IC50 of appr against 30 μM DBTRG-05MG cell. Honokiol-induced apoptosis of GBM cells is associated with the downregulation of the Rb protein and cleavage of PARP and Bcl-x (S/L). Honokiol (50 μM) increases the level of autophagy markers in GBM cells. Honokiol has anticancer effect, and the IC50 values with MDA-MB-231, MDA-MB-468, and MDA-MB-453 cell lines is 16.99 ± 1.28 μM, 15.94 ± 2.35 μM and 20.11 ±3.13 μM respectively. Honokiol (3, 10 μM) produces significant inhibition on the spheroid number and spheroid sizes in the clonogenic assay. Honokiol (0.1-1.0?μM) specifically inhibits washed human platelet aggregation stimulated by collagen, but not by other agonists. honokiol (0.6 and 1.0?μM) can concentration-dependently inhibit the collagen-induced ATP-release reaction in washed human platelets. Honokiol specifically inhibits platelet aggregation and the phosphorylation of Lyn, PLCγ2, and PKC stimulated with convulxin. Honokiol (5, 10?μM) significantly inhibits convulxin-stimulated MAPKs and Akt activation. Medlife has not independently confirmed the accuracy of these methods. They are for reference only. |
||||||||||||
体内研究(In Vivo) |
Honokiol-NM (40 mg/kg, p.o.) produces superior anticancer effects, and the PCNA, Cyclin D1 and cleaved caspase 3 expressions are 2.12, 1.92 and 1.68-fold significantly altered in this treated group. Medlife has not independently confirmed the accuracy of these methods. They are for reference only. |
||||||||||||
运输条件 |
Room temperature or refrigerated transportation. |
||||||||||||
储存方式 |
|
||||||||||||
结构分类 | |||||||||||||
来源 | |||||||||||||
参考文献 |
|
溶解度数据 |
体外研究:
DMSO : ≥ 50 mg/mL (187.74 mM) * "≥" means soluble, but saturation unknown. 配制储备溶液
*
产品不同,其溶解度不同。建议根据产品选择合适的溶剂配制储备溶液;配成溶液后,建议分装保存,避免反复冻融造成的产品失效。 体内研究:
建议根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都建议先按照 体外研究 方式配制澄清的储备液,再依次添加助溶剂:
——为保证实验结果的可靠性,澄清的储备液可以根据储存条件,适当保存;体内实验的工作液,建议您现用现配,当天使用;
以下溶剂前显示的百
*
|
---|
1:一般建议:溶解度为Medlife测试数据,可能与文献描述存在差异。这是由于生产工艺和批次不同产生的正常现象。为了使其更好的溶解,请用37℃加热试管并在超声波水浴中震动片刻。不同批次产品溶解度各有差异,仅做参考,具体以实验方案为准。
2:储存条件:粉末-20°C一般情况可以保存3年,溶于溶剂-80°C一般情况可以保存1年。不同产品及不同批次产品可能存在差异,请细致阅读产品信息,并辅助参考相关文献描述。
Copyright © 2025 陌孚医药 All rights reserved 未经授权禁止拷贝本站所有资料,如有违反,将追究法律责任。
沪ICP备2023012080号 |
沪公网安备31011402010657号